Wang Xin, Xu Zhenyi, Liu Zhilin, Lin Weihao, Cao Zheng, Feng Xiaoli, Gao Yibo, He Jie
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Epidemiology and Biostatistics, School of Public Health, Harbin Medical University, Harbin, China.
Front Genet. 2022 May 23;13:902577. doi: 10.3389/fgene.2022.902577. eCollection 2022.
The immune cell infiltration in TME has been reported to be associated with prognosis and immunotherapy efficiency of lung cancers. However, to date, the immune infiltrative landscape of lung adenocarcinoma (LUAD) has not been elucidated yet. Therefore, this study aimed to identify a new transcriptomic-based TME classification and develop a risk scoring system to predict the clinical outcomes of patients with LUAD. We applied "CIBERSORT" algorithm to analyze the transcriptomic data of LUAD samples and classified LUAD into four discrete subtypes according to the distinct immune cell infiltration patterns. Furthermore, we established a novel predictive tool (TMEscore) to quantify the immune infiltration patterns for each LUAD patient by principal component analysis. The TMEscore displayed as a reliable and independent prognostic biomarker for LUAD, with worse survival in TMEscrore-high patients and better survival in TMEscrore-low patients in both TCGA and other five GEO cohorts. In addition, enriched pathways and genomic alterations were also analyzed and compared in different TMEscore subgroups, and we observed that high TMEscore was significantly correlated with more aggressive molecular changes, while the low TMEscore subgroup enriched in immune active-related pathways. The TMEscore-low subtype showed overexpression of PD-1, CTLA4, and associations of other markers of sensitivity to immunotherapy, including TMB, immunophenoscore (IPS) analysis, and tumor immune dysfunction and exclusion (TIDE) algorithm. Conclusively, TMEscore is a promising and reliable biomarker to distinguish the prognosis, the molecular and immune characteristics, and the benefit from ICIs treatments in LUAD.
肿瘤微环境(TME)中的免疫细胞浸润已被报道与肺癌的预后和免疫治疗效果相关。然而,迄今为止,肺腺癌(LUAD)的免疫浸润格局尚未阐明。因此,本研究旨在确定一种基于转录组的新型TME分类,并开发一种风险评分系统来预测LUAD患者的临床结局。我们应用“CIBERSORT”算法分析LUAD样本的转录组数据,并根据不同的免疫细胞浸润模式将LUAD分为四种不同的亚型。此外,我们通过主成分分析建立了一种新型预测工具(TMEscore)来量化每个LUAD患者的免疫浸润模式。TMEscore显示为LUAD可靠且独立的预后生物标志物,在TCGA和其他五个GEO队列中,TMEscrore高的患者生存率较差,而TMEscrore低的患者生存率较好。此外,还对不同TMEscore亚组中的富集通路和基因组改变进行了分析和比较,我们观察到高TMEscore与更具侵袭性的分子变化显著相关,而低TMEscore亚组则富集于免疫活性相关通路。TMEscore低的亚型显示PD-1、CTLA4过表达,以及其他免疫治疗敏感性标志物的关联,包括肿瘤突变负荷(TMB)、免疫表型评分(IPS)分析和肿瘤免疫功能障碍与排除(TIDE)算法。总之,TMEscore是一种有前景且可靠的生物标志物,可用于区分LUAD的预后、分子和免疫特征以及免疫检查点抑制剂(ICI)治疗的获益情况。